A few questions if I may: 1) Do you know the educational background of Ms Li Kei Ling and Mr Chen Shaojun? 2) Do you know the revenue contribution (in % terms) of the major drugs in their portfolio? 3) Are you concerned that their RMB 150 million JV foray into biotech drug development is indicative of an increased willingness to make speculative investments with their cash? Especially since neither the Chairwoman or CEO appear to have a scientific background? 4) Does management/IR speak to investors outside of the AGM?

Expand full comment